-

ICON and Its Employees Celebrated for Excellence in the Field of Clinical Research

DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured with numerous awards in the second half of 2024.

On TIME Magazine’s 2024 list of World’s Best Companies ICON was ranked as the highest clinical research organisation out of 1,000 companies for the second year in a row, and in its 2025 list of World’s Best Companies in Sustainable Growth it was featured at number 57 out of 500 companies. ICON was also announced as a winner of the Best Practices Recognition award from the Frost and Sullivan Institute’s Enlightened Growth Leadership awards.

ICON was also honoured with a 2024 Scrip award for Best Contract Research Organisation (Full Service Providers). These awards acknowledge the critical role of CROs in delivering specialist outsourced services for all aspects of clinical trials. This is the fifth time ICON has won this coveted industry award in the last eight years.

Two members of ICON’s executive leadership team were acknowledged for professional accomplishment. Barry Balfe was named to the 2024 PharmaVoice 100 List, which recognises the most inspiring leaders in life sciences. Rose Kidd was announced as the recipient of the Businesswoman Award at the 2024 Women Mean Business Awards in Ireland. Additionally, Alexander Murray, an ICON validation specialist, was named IRT Young Professional 2024 at this year’s annual Interactive Response Technology (IRT) Professionals’ Day, celebrating IRT and clinical supply excellence across the industry.

ICON was also recognised across a range of creative and digital marketing awards. Its Creative & Digital Services and Patient Recruitment Services teams won two Health + Wellness awards from Graphic Design USA for the TANGO and ADAMANT study materials, and a Gold Award and Honourable Mention at the MarCom Awards for the same studies in the in the category of “Strategic Communications | Communications/Public Relations | Research/Study.” The MarCom Awards further awarded ICON a Platinum honour for the UCB BE OPEN Study Materials in the same category. ICON also received the Rx Club Show Award of Excellence in the “Direct to Consumer” category.

ICON’s FIRECREST medical animation video, “The Invisible Machine,” won a gold MUSE award whilst at the 2024 Annual International Business Awards, ICON won two Stevie® Awards: Gold for a technology video showcasing AI platforms and wearables, and Bronze for the CARD system, which enhances clinical data distribution. At the 2024 Awards for Technical Excellence, ICON also won a Silver Stevie® for eClinical Development & Delivery’s tokenisation solution.

Steve Cutler, CEO, ICON commented: “It’s fantastic to end the year with recognition for both individual employees as well as ICON as a company. I’m incredibly proud of all the teams and individuals who were honoured in these awards, which demonstrate ICON’s commitment to delivering value and quality in the field of clinical research.”

A full list of ICON’s industry awards can be viewed at www.iconplc.com/awards.

About ICON plc

ICON plc is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employed approximately 42,250 employees in 106 locations in 55 countries as at September 30, 2024. For further information about ICON, visit: www.iconplc.com.

ICON/ICLR-G

Contacts

Claire Quinn, Corporate Communications, ICON
+353 87 4066091
claire.quinn@iconplc.com

Lisa Henry, Weber Shandwick (PR adviser)
+44 7785 458203
lhenry@webershandwick.com

ICON plc

NASDAQ:ICLR

Release Versions

Contacts

Claire Quinn, Corporate Communications, ICON
+353 87 4066091
claire.quinn@iconplc.com

Lisa Henry, Weber Shandwick (PR adviser)
+44 7785 458203
lhenry@webershandwick.com

Social Media Profiles
More News From ICON plc

ICON announces multi-year collaboration with Anthropic to bring frontier AI to clinical trials

DUBLIN--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR) today announced a multi-year collaboration with Anthropic to bring Claude’s AI capabilities across the clinical trial lifecycle. The collaboration further advances ICON’s digital innovation and AI strategy, and builds on Orbis – ICON’s secure, governed, agentic AI platform. Through this collaboration, ICON will work closely with Anthropic’s Life Sciences research team to explore and apply cutting-edge technologies that can accelerate innovation a...

ICON expands US early phase research capabilities with new clinic and outpatient centres

DUBLIN & SAN ANTONIO--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today announced the expansion of its early phase capabilities with the opening of a new, state-of-the-art Clinical Research Unit (CRU) in San Antonio, Texas, as well as new satellite outpatient clinics in Houston, Texas and Lawrence, Kansas. These new, purpose-built clinics will significantly expand ICON’s capacity to conduct first-in-human, healthy participant, and patient cohort stu...

ICON 2025 global biotech survey solidifies China dominance and highlights opportunities for Western biotechs to stay competitive

DUBLIN--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today released findings from two biotech sector surveys. The first survey focused on global biotech trends and is an update of our 2023 survey, while the second survey focused exclusively on trends in the rapidly growing Chinese biotech market. In total, both surveys captured insights from more than 260 biotech professionals and venture capital executives across the US, Europe, Asia-Pacific (APAC)...
Back to Newsroom